• AMP German Cannabis (CSE:XCX) subsidiary, AMP Germany, has received an AMRadV irradiation permit from BfArM
  • Now, the company has all necessary licences to import, store and distribute its irradiated EU-GMP certified medical cannabis flower
  • AMP will store the product at its licensed narcotic storage facility, and distribute it to the company’s pharmaceutical distributors
  • To date, all medical cannabis imported into Germany has been irradiated 
  • AMP’s share price was trading for C$0.29 per share at Thursday’s market close

AMP German Cannabis (CSE:XCX) subsidiary, AMP Alternative Medical Products GmbH, has received an AMRadV irradiation permit from BfArM.

The Federal Institute for Drugs and Medical Devices (BfArM), granted the AMRadV License to the subsidiary, AMP Germany. The permit specifically allows for the distribution of medical cannabis flowers which have undergone ionising radiation treatment.

The company now has all necessary licences to import, store and distribute its irradiated EU-GMP certified medical cannabis flower.

AMP will store the product at its licensed narcotic storage facility and distribute it to pharmaceutical distributors. 

The European Pharmacopoeia defines very specific quality standards for pharmaceutical goods across the continent. EU-GMP medical cannabis imported into Germany should comply with acceptable microbial levels. If they do not, they must undergo microbial sterilisation before becoming available for sale in Germany’s medical cannabis program. 

To date, all medical cannabis that has been imported into Germany has been irradiated, and requires an AMRadV License. 

AMP’s President, Dr Stefan Feuerstein, said that the AMRadV Licence grant is an important last step for AMP’s import capabilities. The company will now be able to import from Europe and elsewhere. 

“AMP will now complete the EU-GMP certification audit of its supply chain, and start the process with the Netherlands Ministry of Health. The Ministry supplies and organises the export of medical cannabis flowers from the Netherlands.

“AMP plans to start imports from the Netherlands in May, and Canada during the latter part of 2020,” he revealed.

AMP’s share price was trading for C$0.29 per share at Thursday’s market close.

More From The Market Online

Xebra Brands receives second CBD approval by Mexican authority

Xebra Brands (CSE:XBRA) announces it has received its second COFEPRIS approval for CBD product authorization in Mexico.
Canopy Growth - CEO, David Klein.

Canopy Growth shareholders approve Canopy USA asset strategy

After rearranging its capital structure, Canopy Growth (TSX:WEED) will be closer to establishing a U.S.-based multi-state operator.

The Market Online’s Weekly Cannabis Report – April 12, 2024

Canada’s cannabis stock market fluctuated this week thanks to a combination of industry-specific developments and broader market trends

Avicanna completes topical gel study

Avicanna (TSX:AVCN) has completed its observational real-world evidence study of its RHO Phyto branded cannabigerol gel.